Intravitreal Infliximab Injection to Treat Experimental Endophthalmitis

Ondas, Osman; Ateş, Orhan; Keleş, Sadullah; Yildirim, Kenan; Baykal, Orhan; Karamese, Selina Aksak; Karameşe, Murat; Uslu, Hakan; Naldan, Muhammet Emin; Ateş, İrem

doi:10.5152/eurasianjmed.2017.17126

Cited by 2 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…156,157 A study on experimental endophthalmitis using S. epidermidis showed that infliximab was as effective as dexamethasone in controlling inflammation when injected intravitreally along with vancomycin. 158 In contrast to this, two studies which compared intravenous and intravitreal infliximab showed significantly better control of inflammation with the intravenous regimen. One of these studies showed no change with intravitreal dose 159 while the other showed exacerbation of inflammation with intravitreal injection.…”

Section: Infliximabmentioning

confidence: 92%

A comprehensive review of intravitreal immunosuppressants and biologicals used in ophthalmology

et al. 2022

View full text Add to dashboard Cite

Systemic immunosuppressants and biologicals have been a valuable tool in the treatment of inflammatory diseases and malignancies. The safety profile of these drugs has been debatable, especially in localized systems, such as the eye. This has led to the search for fairly local approaches, such as intravitreal, subconjunctival, and topical route of administration. Immunosuppressants have been used as a second-line drug in patients intolerable to corticosteroids or those who develop multiple recurrences on weaning corticosteroids. Similarly, biologicals have also been used as the next line of therapy, when adequate control of inflammation could not be attained or immunosuppressants were contraindicated to patients. Intravitreal immunosuppressants, such as methotrexate and sirolimus, have been extensively studied in noninfectious posterior uveitis, whereas limited studies have established the efficacy of intravitreal biologicals, such as infliximab and adalimumab. Most of these drugs have shown good safety profile and tolerability in animal studies alone and have not been studied further in human subjects. However, most of the studies in literature are single-case reports or case series which limits the level of evidence. In this comprehensive review, we discuss the mechanism of action, pharmacodynamics, pharmacokinetics, indications, efficacy, and side effects of different intravitreal immunosuppressants and biologicals that have been studied in literature.

show abstract

Section: Infliximabmentioning

confidence: 92%

A comprehensive review of intravitreal immunosuppressants and biologicals used in ophthalmology

et al. 2022

View full text Add to dashboard Cite

show abstract

Omiganan-Based Synthetic Antimicrobial Peptides for the Healthcare of Infectious Endophthalmitis

Wang,

Ong,

et al. 2024

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Bacterial endophthalmitis is a severe infection of the aqueous or vitreous humor of the eye that can lead to permanent vision loss. Due to the rapid emergence of antibiotic resistance and dose-limiting toxicities, the standard treatment of bacterial endophthalmitis via the intravitreal injection of broad-spectrum antibiotics remains inadequate. Membrane active cationic antimicrobial peptides (AMPs) have emerged as a promising class of effective and broad-spectrum antimicrobial agents with potential to overcome antibiotic resistance. In this work, we investigate, for the first time, the use of omiganan (IK-12), a 12-amino acid indolicidin derivative for the treatment of bacterial endophthalmitis. Additionally, IK-12 was used as a template to perform amino acid rearrangements, without altering the length or type of amino acids, to yield a series of new derivative AMPs with varying extents of secondary structure formation under membrane mimicking conditions. IK-12 and its derivatives demonstrated strong and broad-spectrum antibacterial activities against a panel of clinically isolated Gram-positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus commonly implicated in bacterial endophthalmitis. Interestingly, two of the new IK-12 derivatives, IP-12 and WP-12, showed lower geometric mean minimum inhibitory concentration and higher 50% hemolysis concentration values, which effectively translated into 2-to 3.4-fold higher bacterial selectivity than the parent IK-12. Furthermore, the intravitreal injection of IK-12, IP-12, and WP-12 in a rabbit model of MRSA-induced endophthalmitis led to considerably improved clinical presentation and reduced recruitment of inflammatory cells. In all, these results demonstrate the potential of IK-12 and its derivatives, IP-12 and WP-12, as promising candidates for the treatment of bacterial endophthalmitis.

show abstract

Intravitreal Infliximab Injection to Treat Experimental Endophthalmitis

Cited by 2 publications

References 18 publications

A comprehensive review of intravitreal immunosuppressants and biologicals used in ophthalmology

A comprehensive review of intravitreal immunosuppressants and biologicals used in ophthalmology

Omiganan-Based Synthetic Antimicrobial Peptides for the Healthcare of Infectious Endophthalmitis

Contact Info

Product

Resources

About